Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
10
03
2022
accepted:
22
02
2023
medline:
26
4
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
The B cell-depleting anti-CD20 antibody ocrelizumab (OCR) effectively reduces MS disease activity and slows disability progression. Given the role of B cells as antigen-presenting cells, the primary goal of this study was to evaluate the effect of OCR on the T-cell receptor repertoire diversity. To examine whether OCR substantially alters the molecular diversity of the T-cell receptor repertoire, deep immune repertoire sequencing (RepSeq) of CD4 Peripheral blood samples for RepSeq were obtained from 8 patients with relapsing MS enrolled in the OPERA I trial over a period of up to 39 months. Four patients each were treated with OCR or interferon β1-a during the double-blind period of OPERA I. All patients received OCR during the open-label extension. The diversity of the CD4 Our data illustrate that the diversity of CD4 This is a substudy (BE29353) of the OPERA I (WA21092; NCT01247324) trial. Date of registration, November 23, 2010; first patient enrollment, August 31, 2011.
Sections du résumé
BACKGROUND AND OBJECTIVES
The B cell-depleting anti-CD20 antibody ocrelizumab (OCR) effectively reduces MS disease activity and slows disability progression. Given the role of B cells as antigen-presenting cells, the primary goal of this study was to evaluate the effect of OCR on the T-cell receptor repertoire diversity.
METHODS
To examine whether OCR substantially alters the molecular diversity of the T-cell receptor repertoire, deep immune repertoire sequencing (RepSeq) of CD4
RESULTS
Peripheral blood samples for RepSeq were obtained from 8 patients with relapsing MS enrolled in the OPERA I trial over a period of up to 39 months. Four patients each were treated with OCR or interferon β1-a during the double-blind period of OPERA I. All patients received OCR during the open-label extension. The diversity of the CD4
DISCUSSION
Our data illustrate that the diversity of CD4
TRIAL REGISTRATION INFORMATION
This is a substudy (BE29353) of the OPERA I (WA21092; NCT01247324) trial. Date of registration, November 23, 2010; first patient enrollment, August 31, 2011.
Identifiants
pubmed: 37094998
pii: 10/4/e200118
doi: 10.1212/NXI.0000000000200118
pmc: PMC10136682
pii:
doi:
Substances chimiques
ocrelizumab
A10SJL62JY
Immunologic Factors
0
Antibodies, Monoclonal, Humanized
0
Receptors, Antigen, T-Cell
0
Banques de données
ClinicalTrials.gov
['NCT01247324']
Types de publication
Clinical Trial, Phase III
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : K02 NS072288
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS092835
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Eur Neurol. 2015;73(3-4):238-246
pubmed: 25824054
Genetics. 1931 Mar;16(2):97-159
pubmed: 17246615
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 23;9(1):
pubmed: 34815322
J Neurol. 2022 Oct;269(10):5443-5453
pubmed: 35652942
JAMA Neurol. 2021 Dec 1;78(12):1510-1514
pubmed: 34554197
Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9773-9778
pubmed: 30194232
Arch Neurol. 2010 Jun;67(6):707-14
pubmed: 20558389
Eur J Immunol. 2016 Feb;46(2):480-92
pubmed: 26614343
Sci Immunol. 2017 Sep 29;2(15):
pubmed: 28963118
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13139-44
pubmed: 25157137
J Neuroinflammation. 2015 Jan 28;12:19
pubmed: 25626447
J Immunol. 2016 Jun 15;196(12):5005-13
pubmed: 27183615
Ann Neurol. 2008 Mar;63(3):395-400
pubmed: 18383069
Blood. 2018 Apr 5;131(14):1545-1555
pubmed: 29378696
Sci Transl Med. 2022 Mar 30;14(638):eabi4632
pubmed: 35353539
JCI Insight. 2017 Jun 15;2(12):
pubmed: 28614800
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32573488
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25690-25699
pubmed: 32999069
Genome Med. 2016 Jun 03;8(1):60
pubmed: 27255379
Virus Evol. 2018 Nov 28;4(2):vey034
pubmed: 30524754
Curr Opin Immunol. 2013 Oct;25(5):646-52
pubmed: 24140071
JCI Insight. 2017 Sep 7;2(17):
pubmed: 28878127
J Neurol. 2021 Oct;268(10):3592-3594
pubmed: 33638680
J Exp Med. 2008 Mar 17;205(3):711-23
pubmed: 18332179
J Immunol. 2014 Jul 15;193(2):580-586
pubmed: 24928997
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20066-71
pubmed: 22123975
Neurology. 2020 Sep 29;95(13):e1854-e1867
pubmed: 32690791
Mult Scler Relat Disord. 2022 Apr;60:103740
pubmed: 35305426
Front Immunol. 2014 Mar 19;5:96
pubmed: 24678310
Eur J Immunol. 2012 Nov;42(11):3073-83
pubmed: 22806588
Proc Natl Acad Sci U S A. 2010 Mar 9;107(10):4658-63
pubmed: 20176942
Br J Clin Pharmacol. 2021 Jun;87(6):2511-2520
pubmed: 33202059
Nat Immunol. 2018 Jul;19(7):696-707
pubmed: 29925992
JCI Insight. 2017 Nov 16;2(22):
pubmed: 29202449
Ann Neurol. 2018 Jan;83(1):13-26
pubmed: 29244240
J Clin Invest. 2012 Dec;122(12):4533-43
pubmed: 23160197
Ann Clin Transl Neurol. 2014 Aug;1(8):622-31
pubmed: 25356432
Neurology. 2020 Oct 6;95(14):e1999-e2008
pubmed: 32727835
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25800-25807
pubmed: 31748274
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679
Mol Biol Evol. 2016 Nov;33(11):3002-3027
pubmed: 27550904